New hope for esophageal cancer patients after first treatment fails

NCT ID NCT07530549

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose initial chemo-immunotherapy did not work. About 40 participants will receive the treatment, and doctors will monitor for tumor shrinkage, survival, and side effects. Some patients may also have surgery afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and Tuvonralimab (QL1706) combined with chemoradiotherapy
What this could lead to: If successful, this could offer a new treatment option for people with advanced esophageal cancer whose first therapy stopped working.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The combination therapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCAL ADVANCED ESOPHAGEAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.